|
1.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Estimating the world cancer burden: Globocan 2000. Int J Cancer.
94:153–156. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Flehinger BJ, Kimmel M, Polyak T and
Melamed MR: Screening for lung cancer. The Mayo Lung Project
revisited. Cancer. 72:1573–1580. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Strauss GM: Measuring effectiveness of
lung cancer screening: from concensus to controversy and back.
Chest. 112(Suppl 4): 216S–228S. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Amos CI, Xu W and Spitz MR: Is there a
genetic basis for lung cancer susceptibility? Recent Results Cancer
Res. 151:3–12. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Wood ME, Kelly K, Mullineaux LG and Bunn
PA Jr: The inherited nature of lung cancer: a pilot study. Lung
Cancer. 30:135–144. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Kopreski MS, Benko FA, Borys DJ, Khan A,
McGarrity TJ and Gocke CD: Somatic mutation screening:
identification of individuals harboring K-Ras mutations with the
use of plasma DNA. J Natl Cancer Inst. 92:918–923. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Forgacs E, Zöchbauer-Müller S, Oláh E and
Minna JD: Molecular genetic abnormalities in the pathogenesis of
human lung cancer. Pathol Oncol Res. 7:6–13. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the Epidermal Growth
Factor Receptor gene in lung cancer: Biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar
|
|
9.
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, et al: Clinical and biological
features associated with epidermal growth factor receptor gene
mutations in lung cancers. J Natl Cancer Inst. 97:339–346. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Chang JW, Liu HP, Hsieh MH, Fang YF, Hsieh
MS, Hsieh JJ, Chiu YT, et al: Increased epidermal growth factor
receptor (EGFR) gene copy number is strongly associated with EGFR
mutations and adenocarcinoma in non-small cell lung cancers: a
chromogenic in situ hybridization study of 182 patients. Lung
Cancer. 61:328–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Sasaki H, Endo K, Okuda K, Kawano O,
Kitahara N, Tanaka H, Matsumura A, et al: Epidermal growth factor
gene amplification and gefitinib sensitivity in patients with
recurrent lung cancer. J Cancer Res Clin Oncol. 134:569–577. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Giaccone G, Gallegos Ruiz M, Le Chevalier
T, Thatcher N, Smit E, Rodriguez JA, Janne P, et al: Erlotinib for
frontline treatment of advanced non-small cell lung cancer: a phase
II study. Clin Cancer Res. 12:6049–6055. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Bos JL: ras oncogenes in human cancer: a
review. Cancer Res. 49:4682–4689. 1989.PubMed/NCBI
|
|
14.
|
Benvenuti S, Sartore-Bianchi A, Di
Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S and Bardelli
A: Oncogenic activation of the RAS/RAF signaling pathway impairs
the response of metastatic colorectal cancers to anti-epidermal
growth factor receptor antibody therapies. Cancer Res.
67:2643–2648. 2007. View Article : Google Scholar
|
|
15.
|
Oldenhuis CN, Oosting SF, Gietema JA and
de Vries EG: Prognostic versus predictive value of biomarkers in
oncology. Eur J Cancer. 44:946–53. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Linardou H, Dahabreh IJ, Kanaloupiti D,
Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA and Murray S:
Assessment of somatic k-RAS mutations as a mechanism associated
with resistance to EGFR-targeted agents: a systematic review and
meta-analysis of studies in advanced non-small-cell lung cancer and
metastatic colorectal cancer. Lancet Oncol. 9:962–972. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Sasaki H, Shimizu S, Okuda K, Kawano O,
Yukiue H, Yano M and Fujii Y: Epidermal growth factor receptor gene
amplification in surgical resected Japanese lung cancer. Lung
Cancer. 64:295–300. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Pao W, Wang TY, Riely GJ, Miller VA, Pan
Q, Ladanyi M, Zakowski MF, et al: KRAS mutations and primary
resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS
Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Hemming AW, Davis NL, Kluftinger A,
Robinson B, Quenville NF, Liseman B and LeRiche J: Prognostic
markers of colorectal cancer: an evaluation of DNA content,
epidermal growth factor receptor, and Ki-67. J Surg Oncol.
51:147–152. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, et al: EGF receptor gene mutations
are common in lung cancers from ‘never smokers’ and are associated
with sensitivity of tumors to gefitinib and erlotinib. Proc Natl
Acad Sci USA. 101:13306–13311. 2004.
|
|
21.
|
Rusch V, Baselga J, Cordon-Cardo C, Orazem
J, Zaman M, Hoda S, McIntosh J, et al: Differential expression of
the epidermal growth factor receptor and its ligands in primary
non-small cell lung cancers and adjacent benign lung. Cancer Res.
53(Suppl 10): 2379–2385. 1993.PubMed/NCBI
|
|
22.
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Le Calvez F, Mukeria A, Hunt JD, Kelm O,
Hung RJ, Tanière P, Brennan P, Boffetta P, et al: TP53 and KRAS
mutation load and types in lung cancers in relation to tobacco
smoke: distinct patterns in never, former, and current smokers.
Cancer Res. 65:5076–5083. 2005.PubMed/NCBI
|
|
24.
|
Tam IY, Chung LP, Suen WS, Wang E, Wong
MC, Ho KK, Lam WK, et al: Distinct epidermal growth factor receptor
and KRAS mutation patterns in non-small cell lung cancer patients
with different tobacco exposure and clinicopathologic features.
Clin Cancer Res. 12:1647–1653. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, et al: EGFR mutations in lung
cancer: correlation with clinical response to gefitinib therapy.
Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Sugio K, Uramoto H, Ono K, Oyama T,
Hanagiri T, Sugaya M, Ichiki M, et al: Mutations within the
tyrosine kinase domain of EGFR gene specifically occur in lung
adenocarcinoma patients with a low exposure of tobacco smoking. Br
J Cancer. 94:896–903. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Tokumo M, Toyooka S, Kiura K, Shigematsu
H, Tomii K, Aoe M, Ichimura K, et al: The relationship between
epidermal growth factor receptor mutations and clinicopathologic
features in non-small cell lung cancers. Clin Cancer Res.
11:1167–1173. 2005.PubMed/NCBI
|
|
29.
|
Pham D, Kris MG, Riely GJ, Sarkaria IS,
McDonough T, Chuai S, Venkatraman ES, et al: Use of
cigarette-smoking history to estimate the likelihood of mutations
in epidermal growth factor receptor gene exons 19 and 21 in lung
adenocarcinomas. J Clin Oncol. 24:1700–1704. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Lee YJ, Shim HS, Kang YA, Hong SJ, Kim HK,
Kim H, Kim SK, et al: Dose effect of cigarette smoking on frequency
and spectrum of epidermal growth factor receptor gene mutations in
Korean patients with non-small cell lung cancer. J Cancer Res Clin
Oncol. 136:1937–1944. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Mitsudomi T, Kosaka T, Endoh H, Horio Y,
Hida T, Mori S, et al: Mutations of the epidermal growth factor
receptor gene predict prolonged survival after gefitinib treatment
in patients with non-small-cell lung cancer with postoperative
recurrence. J Clin Oncol. 23:2513–2520. 2005. View Article : Google Scholar
|
|
32.
|
Samowitz WS, Curtin K, Schaffer D,
Robertson M, Leppert M and Slattery ML: Relationship of Ki-ras
mutations in colon cancers to tumor location, stage, and survival:
a population-based study. Cancer Epidemiol Biomarkers Prev.
9:1193–1197. 2000.PubMed/NCBI
|
|
33.
|
Keller JW, Franklin JL, Graves-Deal R,
Friedman DB, Whitwell CW and Coffey RJ: Oncogenic KRAS provides a
uniquely powerful and variable oncogenic contribution among RAS
family members in the colonic epithelium. J Cell Physiol.
210:740–749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Wang JY, Wang YH, Jao SW, Lu CY, Kuo CH,
Hu HM, Hsieh JS, et al: Molecular mechanisms underlying the
tumorigenesis of colorectal adenomas: correlation to activated
K-Ras oncogene. Oncol Rep. 16:1245–1252. 2006.PubMed/NCBI
|
|
35.
|
Pfeifer GP, Denissenko MF, Olivier M,
Tretyakova N, Hecht SS and Hainaut P: Tobacco smoke carcinogenesis,
DNA damage and p53 mutations in smoking-associated cancers.
Oncogene. 21:7435–7451. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Pines G, Köstler WJ and Yarden Y:
Oncogenic mutant forms of EGFR: lessons in signal transduction and
targets for cancer therapy. FEBS Lett. 584:2699–2706. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Schmid K, Oehl N, Wrba F, Pirker R, Pirker
C and Filipits M: EGFR/KRAS/BRAF mutations in primary lung
adenocarcinomas and corresponding locoregional lymph node
metastases. Clin Cancer Res. 15:4554–4560. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Han SW, Kim TY, Jeon YK, Hwang PG, Im SA,
Lee KH, Kim JH, et al: Optimization of patient selection for
gefitinib in non-small cell lung cancer by combined analysis of
epidermal growth factor receptor mutation, K-Ras mutation, and Akt
phosphorylation. Clin Cancer Res. 12:2538–2544. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
van Zandwijk N, Mathy A, Boerrigter L,
Ruijter H, Tielen I, de Jong D, Baas P, et al: EGFR and KRAS
mutations as criteria for treatment with tyrosine kinase
inhibitors: retro- and prospective observations in non-small-cell
lung cancer. Ann Oncol. 18:99–103. 2007.PubMed/NCBI
|
|
40.
|
Massarelli E, Varella-Garcia M, Tang X,
Xavier AC, Ozburn NC, Liu DD, Bekele BN, et al: KRAS mutation is an
important predictor of resistance to therapy with epidermal growth
factor receptor tyrosine kinase inhibitors in non-small-cell lung
cancer. Clin Cancer Res. 13:2890–2896. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Yamanaka S, Gu Z, Sato M, Fujisaki R,
Inomata K, Sakurada A, Inoue A, et al: siRNA targeting against
EGFR, a promising candidate for a novel therapeutic application to
lung adenocarcinoma. Pathobiology. 75:2–8. 2008. View Article : Google Scholar : PubMed/NCBI
|
